Researchers at MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a phase I clinical trial.
Working in a comprehensive cancer center requires emotional endurance, strong clinical judgment, and constant interprofessional collaboration, all of which rest on a foundation of personal wellness. For nurses, whose roles are inherently intensive, focusing on wellbeing is integral to their ability to provide safe, compassionate, and effective patient care.
